At a glance

ClinicalIndex Comparison Record

N/AActive· 26 enrolled

Drug / intervention

Dietary Intervention +2 moredietary

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04310826

NCT04310826N/AActive

Compare CT.gov

Feasibility of Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Ovarian Cancer Patients Receiving Carboplatin Chemotherapy

M.D. Anderson Cancer Center·interventional·Posted Mar 17, 2020·Updated Feb 17, 2026

In Brief

A clinical study evaluating Dietary Intervention, Media Intervention, and 1 other intervention for Ovarian Carcinoma. Active but no longer recruiting, targeting 26 participants across 1 site.

Detailed Summary

This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsOvarian Carcinoma

CountriesUnited States

CollaboratorsNational Cancer Institute (NCI)

Timeline

N/AActiveOverdue

2020202120222023202420252026

Enrollment StartApr 2019

First PostedMar 2020

Primary CompletionApr 2026

TodayJul 2026

First PostedMar 17, 2020

Enrollment StartApr 23, 2019

Primary CompletionApr 1, 2026

TodayJul 1, 2026

Enrollment to primary: 6.9 yearsPosted 6.3 years ago

Interventions

Dietary Interventiondietary

Receive dietary magnesium intervention

Media Interventionother

Undergo video interviews

Telephone-Based Interventionbehavioral

Receive phone calls